LLY
HOLDEli Lilly and Company
$1071.44+14.44 (+1.37%)
Market Cap: 960.50B
HealthcareDrug Manufacturers - General
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company focuses on endocrinology, oncology, neuroscience, and immunology. It has seen significant growth driven by its portfolio of diabetes and obesity treatments, including Mounjaro and Zepbound.
Profit Margin
30.99%
Keep per $1 revenue
Return On Equity
96.47%
Efficiency Score
Analyst Target
$1093.22
Consensus Fair Value
52-Week High
$1111.99
Yearly Ceiling
Price Performance
+0 (+0%)past 1Y
Drawdown Risk
How to read this chart:
Shows the percentage drop from the highest price in the selected period.
- • 0% = Stock is at a peak.
- • -20% = Fallen 20% from the top.
Risk Intelligence
Sharpe Ratio1.23
Score > 1.0 is Excellent
Beta (Volatility)0.37
1.0 = Moves with S&P 500
Sortino Ratio1.78
Financial Flow
Total Revenue$45.04B
Costs$8.42B
Gross Profit$36.62B
Net Earnings$10.59B